1-甲基哌嗪盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-甲基哌嗪盐酸盐
• 中文别名: 甲基哌嗪盐酸盐；1-甲基哌嗪双盐酸盐；N-甲基哌嗪盐酸盐
• 英文名称: 1-Methylpiperazin-1-ium;chloride;hydrochloride
• 英文别名: 1-methylpiperazin-1-ium;chloride;hydrochloride
• 化学式: C5H14Cl2N2
• mdl: MFCD00012755
• 分子量: 173.08
• InChiKey: AILFRWRYZZVJTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.35
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基哌嗪盐酸盐 、 二聚氰胺 以75%的产率得到
  参考文献：
  名称：

  ZIKOLOVA, S.;SLAVOVA, S.;XADZHIEVA, K., TR. N.-I. XIM.-FARM. IN-T, NRB, 1985, 15, 13-20

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-methylpiperazin-1-yl)-2-(1,4,5,6-tetrahydropyrimidin-2-ylsulfanyl)ethanone;dihydrochloride 、 乙醇 以77%的产率得到
  参考文献：
  名称：

  GROSHKOVSKI, S.;KREZHEL, I.;KOZHYTSKA, L., XIMIYA GETEROTSIKL. SOEDIN., 1984, N 6, 823-826

  摘要：

  DOI：

文献信息

• [EN] N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE<br/>[FR] PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES N-SULFONYLÉS ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ABBVIE S Á R L

  公开号：WO2017060874A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了一种具有以下结构的化合物（I），其中R1、R2、R3、R4、R5和R6具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个具有结构（I）的化合物组成的药物组合物。
• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。
• [EN] COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS QUI POTENTIALISENT LE RÉCEPTEUR AMPA ET LEURS UTILISATIONS EN MÉDECINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009053448A1

  公开（公告）日：2009-04-30

  The invention provides compounds of formula (I) and salts thereof wherein R1, R2, R3, R4 and X are as defined in the description. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  该发明提供了式（I）的化合物及其盐，其中R1、R2、R3、R4和X如描述中所定义。还公开了制备方法、药物组合物以及将其用作药物的用途，例如在治疗由谷氨酸受体功能减少或失衡介导的疾病或症状，如精神分裂症或认知障碍。
• [EN] THIAZEPINE INHIBITORS OF HIV-1 INTEGRASE<br/>[FR] INHIBITEURS DE L'INTEGRASE DU VIH-1 A BASE DE THIAZEPINE
  申请人：US HEALTH

  公开号：WO2000068235A1

  公开（公告）日：2000-11-16

  The present invention discloses non-catechol compounds, such as thiazolothiazepines, and analogs and derivatives thereof, which are anti-integrase inhibitors. The compounds, which are useful as treatments for HIV disease, include compounds (I), (II), (III), or pharmaceutically acceptable salts thereof wherein A is thiazole, benzene, naphthalene, pyridine, pyrimidine, pyrazine, or quinoline; R is one or more of H, halogen, lower alkyl, lower alkoxy, NO2, lower ester or carboxylic acid; X-Y is CH2-S, S-CH2, CH2-O, CH2-S(O), S(O)-CH2, CH2-CH2, CH2-CH2-CH2, or CH2-CH2-CH2-CH2; R4 is H or hydroxy; R5 is H, phenyl, or alkylamine; W is S or O; and R6 is H, substituted or unsubstituted alkyl or amine; and Z is S, O, CH2, CH2CH2, or C=O.

  本发明揭示了非儿茶酚化合物，例如噻唑噻唑烷以及其类似物和衍生物，它们是抗整合酶抑制剂。这些化合物可用作治疗艾滋病的药物，包括化合物（I）、（II）、（III）或其药学上可接受的盐，其中A是噻唑，苯，萘，吡啶，嘧啶，吡嗪或喹啉；R是H，卤素，低碳基，低氧基，NO2，低酯或羧酸之一或多个；X-Y是CH2-S，S-CH2，CH2-O，CH2-S（O），S（O）-CH2，CH2-CH2，CH2-CH2-CH2或CH2-CH2-CH2-CH2；R4是H或羟基；R5是H，苯基或烷基胺；W是S或O；R6是H，取代或未取代的烷基或胺基；Z是S，O，CH2，CH2CH2或C=O。
• Amino carbonyl derivatives of benzofurans, processes for their
  申请人：Kali-Chemie Aktiengesellschaft

  公开号：US04009184A1

  公开（公告）日：1977-02-22

  Compounds which are amino carbonyl derivatives of benzofurans which have the formula ##STR1## in which R is a hydrogen, halogen, or alkyl radical containing up to 4 carbon atoms, X is a phenyl, halophenyl, alkylphenyl, or alkoxyphenyl radical, the alkyl moieties of which contain up to 4 carbon atoms, and Y is a dialkylamino radical, the alkyl moieties of which contain up to 4 carbon atoms, or a pyrrolidino, piperidino, hexamethylenimino, morpholino, piperazino, 4-methylpiperazino, or 4-(2-hydroxyethyl)piperazino radical, and acid addition salts thereof, processes for their preparation, and pharmaceutical compositions containing these compounds.

  这是一段有关化合物的描述，化合物是苯并呋喃的氨基羰基衍生物，其化学式为##STR1##其中R为氢、卤素或含有最多4个碳原子的烷基基团，X为苯基、卤苯基、烷基苯基或烷氧基苯基基团，其烷基部分含有最多4个碳原子，Y为二烷基氨基基团，其烷基部分含有最多4个碳原子，或吡咯烷基、哌啶基、六亚甲基亚胺基、吗啉基、哌嗪基、4-甲基哌嗪基或4-(2-羟乙基)哌嗪基团，以及它们的酸加成盐，以及制备它们的过程和含有这些化合物的药物组合物。